Testing JMKX003142 for Fast-Progressing Polycystic Kidney Disease
Tests the drug JMKX003142 against a placebo in adults with fast-progressing polycystic kidney disease.
Plain-language title generated from the registry record
Registry title: Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 55 with rapidly progressive autosomal dominant polycystic kidney disease (ADPKD).
- Age
- 18 to 55 years
- Sex
- Men and women
- Disease stage
- ADPKD that meets the diagnostic criteria and the criteria for rapidly progressive disease.
- Earlier treatment
- People cannot have taken tolvaptan or another ADPKD medicine in the 12 weeks before screening. They cannot have had surgery to relieve pressure from kidney cysts. They cannot have had major surgery in the 12 weeks before signing consent.
Main reasons for not taking part
- Took tolvaptan or another ADPKD medicine in the 12 weeks before screening
- Likely to use a diuretic during the trial
- Cannot feel thirst or has trouble with fluid or food intake
- Had surgery to relieve pressure from kidney cysts
- Had major surgery in the 12 weeks before signing consent
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT06800651, who can take part
Where in China
- Peking University First HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jemincare
- Trial code
- NCT06800651
- Record updated
- 3 July 2025
- Original description
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants with Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)Read full original descriptionShow less
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants with Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Inclusion: Able to understand the procedures of this trial and provide written informed consent voluntarily; Age between 18 to 55 years, male or female; ADPKD diagnostic criteria were met before randomization; Rapidly progressive ADPKD criteria were met.
Exclusion: 12 weeks prior to screening, patients had taken tolvaptan or another ADPKD improvers, or patients who were assessed by the investigator to be likely to use diuretic during the trial period; Patients who have previously received decompression surgery for renal cysts; or who received major surgery within 12 weeks before signing the ICF; Praticipants who are unable to feel thirst, or have difficulty with fluid/food intake; The investigator think that the praticipant is unable to comply with the requirements of the trial or cannot be evaluated by the trial.